Actively Recruiting
Safety and Effectiveness of Psilocybin Therapy for Depression in Adults with Non-Small Cell Lung Cancer
Led by Alan Davis · Updated on 2026-05-14
10
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and side effects of psilocybin combined with therapy to treat major depressive disorder in patients with non-small cell lung cancer NSCLC. This phase II trial focuses on patients facing psychological symptoms such as depression, anxiety, and existential distress that often accompany a lung cancer diagnosis. Psilocybin, derived from the mushroom Psilocybe mexicana, is being studied for its potential to affect brain activity and hallucinations in combination with therapy in this patient group. Participants attend two preparation therapy sessions lasting 4 hours each on days 7 and 14. On day 21, they receive a single oral dose of psilocybin followed by a therapy session lasting 8 to 10 hours. After dosing, participants complete two post-dosing therapy sessions of 2 hours each on days 22 and 28. Blood and urine samples are collected throughout the study period to monitor effects and safety. During the study, participant depression levels, quality of life, cancer-related stress, and existential distress are assessed using various questionnaires and rating scales. Primary outcomes include ratings of suicidal thoughts, adverse events, and therapy acceptability and satisfaction, measured at baseline, one day, and four weeks after the psilocybin dose. Follow-up visits occur at 4 and 12 weeks after treatment to monitor ongoing effects and safety.
CONDITIONS
Brief Title
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
Research Team
O
Ohio State University Comprehensive Cancer Center
M
Michelle Pham, M.S.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here